Adagene (ADAG) Share-based Compensation (2020 - 2025)
Adagene's (ADAG) quarterly Share-based Compensation came in at $5.2 million in Q4 2025, down 10.27% year-on-year from $5.8 million in Q4 2024, and down 10.27% on a QoQ basis from $5.8 million in Q4 2024.
Adagene (ADAG) Share-based Compensation (2020 - 2025) Analysis & Trends
Adagene (ADAG) has 6 years of Share-based Compensation data on file, last reported at $5.2 million in Q4 2025.
- On a quarterly basis, Share-based Compensation fell 10.27% year-over-year to $5.2 million in Q4 2025; TTM through Dec 2025 was $5.2 million, a 10.27% decrease from a year earlier, with the FY2025 full-year figure at $5.2 million, down 10.27% from the prior year.
- Share-based Compensation for Q4 2025 stood at $5.2 million, down from $5.8 million in the prior quarter.
- Over the last five years, Share-based Compensation for ADAG reached as high as $30.6 million in Q4 2021 and fell as low as $5.2 million in Q4 2025.
- Historically, Share-based Compensation has averaged $16.4 million across 5 years, with a median of $16.7 million in 2023.
- Across the five-year window, Share-based Compensation declined 10.23% in 2021 and sank 65.32% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $30.6 million in 2021, then decreased by 22.78% to $23.6 million in 2022, then fell by 29.52% to $16.7 million in 2023, then sank by 65.32% to $5.8 million in 2024, then declined by 10.27% to $5.2 million in 2025.
- Per Business Quant data, the three most recent Share-based Compensation figures were $5.2 million in Q4 2025, $5.8 million in Q4 2024, and $16.7 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Adagene | 198.85 Mn | 198.85 Mn | - | 5.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.18 Mn |
| Dec 31, 2025 | 5.18 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Dec 31, 2023 | 16.66 Mn |
| Dec 31, 2023 | 16.66 Mn |
| Dec 31, 2022 | 23.64 Mn |
| Dec 31, 2022 | 23.64 Mn |
| Dec 31, 2021 | 30.61 Mn |
| Dec 31, 2021 | 30.61 Mn |
| Dec 31, 2020 | 34.10 Mn |
| Dec 31, 2020 | 34.10 Mn |